Trial Profile
Study of the combination of reduced-intensity conditioning (188)rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Busulfan; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 13 Jul 2016 New trial record